Oppenheimer on Prometheus Biosciences Inc (RXDX): 'We view the top-line results in UC as among the best for any product in a Phase 2 study to date'
Tweet Send to a Friend
Oppenheimer analyst Jeff Jones reiterated an Outperform rating on Prometheus Biosciences Inc (NASDAQ: RXDX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
